Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

KPV

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Systemic Dose

200–400mcg

Once daily by community subcutaneous protocol.

Oral Gut Dose

200–500mcg

Once or twice daily in community protocols.

Class

Tripeptide

Review the full protocol details below.

Primary Use

Inflammation

Review the full protocol details below.

Peptide Grade

GradeB

KPV combines a focused anti-inflammatory mechanism with compelling gut, skin, and PepT1 research plus strong community interest; the absence of human trials limits the grade.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What is KPV?

KPV is a tripeptide composed of lysine, proline, and valine. It is the C-terminal three-amino-acid sequence of alpha-melanocyte-stimulating hormone, or alpha-MSH.

Researchers found that much of the anti-inflammatory activity associated with alpha-MSH could be retained in this short terminal sequence. KPV can suppress inflammatory signaling while avoiding the strong pigment-producing activity associated with full melanocortin agonists.

KPV is unusually small, with a molecular mass of approximately 343 daltons in its unmodified free form. Its size and tripeptide structure make it suitable for investigation through oral, topical, and injectable delivery systems.

Inflammation Without Tanning

KPV does not reproduce the tanning, appetite, or sexual effects associated with melanocortin agonists such as MT-1 or MT-2. Its anti-inflammatory activity appears to be at least partly independent of classical MC1R signaling, although the full receptor and intracellular mechanism is still being defined.

In intestinal research, KPV can be transported into epithelial and immune cells by peptide transporter 1, or PepT1. PepT1 is normally most active in the small intestine but can be upregulated in inflamed colonic tissue.

Published KPV evidence remains preclinical. The research base consists primarily of cell experiments and animal models, especially mouse models of colitis, inflammation, and colitis-associated cancer.

Potential KPV Benefits

All disease-related applications below are based on laboratory or animal research rather than completed human clinical trials.

Gut Inflammation & Colitis

Oral KPV reduced disease severity, inflammatory cytokine expression, and tissue injury in DSS- and TNBS-induced mouse colitis. PepT1-dependent uptake appears central to its intestinal activity.

Broader Anti-Inflammatory Activity

KPV and related alpha-MSH fragments have shown anti-inflammatory effects in preclinical models involving dermatitis, arthritis, allergic airway inflammation, brain injury, and intestinal disease.

Antimicrobial Activity

Alpha-MSH C-terminal peptides have demonstrated direct activity against organisms including Staphylococcus aureus and Candida albicans. They did not impair neutrophil killing and enhanced it in early experiments.

Skin Inflammation

Preclinical work supports local anti-inflammatory potential in skin and mucosal tissue. Claims involving psoriasis, eczema, or wound healing remain experimental and are not supported by human trials.

Barrier Support

KPV delivery systems have reduced inflammatory signaling and supported tight-junction and mucosal-healing markers in experimental colitis models.

Colitis-Associated Cancer Research

In a 2016 mouse model, PepT1-mediated KPV treatment reduced colitis-associated tumor development. This was context-specific animal evidence and does not establish human cancer prevention.

Protocol Planning

Dosing, cycling, and preparation

KPV Dosing Protocol

These are community protocols. No human dose-ranging trial has established an effective dose, route, duration, or long-term treatment schedule.

Systemic Community Protocol

Dose

200–400mcg once daily

Route

Subcutaneous injection

Duration

4–8 weeks

Community Use

Systemic inflammatory or autoimmune-support goals

Oral Gut-Focused Protocol

Dose

200–500mcg once or twice daily

Route

Oral capsule or solution

Duration

4–8 weeks; some users extend with monitoring

Community Use

Gut inflammation and intestinal-barrier support

PepT1 Supports a Plausible Oral Mechanism

Cell and mouse studies show PepT1-mediated KPV uptake and benefit from oral administration. This supports oral investigation for intestinal targets but does not establish human oral bioavailability or clinical effectiveness.

KPV Reconstitution

The following standard example uses a 10mg vial with 2mL of bacteriostatic water.

10mg Vial

Vial Size

10mg

BAC Water

2mL

Concentration

5mg/mL

200mcg

4 units on a U-100 syringe

400mcg

8 units

Reconstitution Calculator

Handling Notes

Mixing

Add bacteriostatic water to the vial.

Do Not

Do not shake aggressively.

Storage

Refrigerate after reconstitution.

Product Quality

Use only product-specific validated storage guidance when available.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Reduced bloating is one of the more common reports during oral use.
Some users describe improved digestion within two to four weeks.
A calmer or less irritated gastrointestinal feeling is frequently mentioned.

Negative Reports

Results in suspected IBD or chronic intestinal conditions are highly variable, ranging from meaningful improvement to no noticeable effect.
Mild injection-site irritation and occasional gastrointestinal upset at higher oral doses are the most commonly reported side effects.

Stacking & Synergy

Potential KPV pairings and tracking context

KPV Stacking & Synergy

KPV + BPC-157

This is a common community pairing for gut-focused protocols. KPV is intended to address inflammatory signaling, while BPC-157 is used for experimental tissue-repair goals. No published combination study exists.

KPV + GLP-1 Agonists

No established interaction data exists. KPV is sometimes discussed for inflammatory gastrointestinal symptoms during semaglutide or retatrutide use, but it has not been studied as a treatment for GLP-1-related nausea, constipation, vomiting, or abdominal pain.

KPV + GHK-Cu

Commercial and community blends increasingly combine KPV with GHK-Cu. Some users report that KPV appears to reduce the familiar sting or burning from subcutaneous GHK-Cu injections. This is anecdotal and has not been tested in a controlled study.

Reduced injection discomfort does not prove that KPV chemically stabilizes GHK-Cu, prevents tissue irritation, or makes a compounded blend sterile or safe.

Free with login

Track in Journal

Track KPV with the markers that matter most for this compound.

Dose, route, timing, and cycle day.
Bloating, digestion, abdominal discomfort, and food tolerance.
Bowel pattern, skin symptoms, inflammation, and side effects.

Start Tracking

Common Questions

Common questions about KPV

Does KPV darken the skin like MT-1 or MT-2?

KPV is not known to produce the tanning, appetite, or sexual effects of melanocortin agonists. Its anti-inflammatory effects appear at least partly independent of MC1R signaling. Saying it has absolutely no receptor activity is stronger than the evidence supports.

Is oral KPV effective, or do I need to inject it?

PepT1 transport and oral benefit have been demonstrated in cell and mouse studies, especially in inflamed intestinal tissue. This makes oral delivery biologically plausible for gut targets, but human absorption and efficacy have not been established. Subcutaneous superiority for systemic use is also unproven.

Is there any human clinical data?

No published human intervention trial was identified. Current evidence remains preclinical, including cell experiments, conventional animal studies, and newer targeted-delivery research.

How is KPV different from ibuprofen or prednisone?

KPV modulates inflammatory pathways such as NF-kB and MAP kinase in experimental systems. NSAIDs and corticosteroids are approved medicines with extensive human efficacy, dosing, interaction, and safety data. KPV does not have comparable human evidence and should not be treated as a proven substitute.

Can KPV help with autoimmune conditions?

KPV has activity in several animal inflammatory models, but no human autoimmune indication has been established. People using immunosuppressive or immune-modulating medication should involve their physician before considering an experimental peptide.

Safety Notes

Side effects, contraindications, and precautions

KPV Side Effects

Preclinical studies generally describe KPV and related alpha-MSH fragments as well tolerated. The absence of human clinical trials leaves important short- and long-term safety questions unanswered.

Good tolerability in cell and animal studies does not establish safety for repeated oral, topical, or injectable use in humans.

Published Research / Preclinical Tolerability

Reviews describe KPV-related tripeptides as having favorable physicochemical and preclinical safety characteristics.
Animal and cell studies generally have not emphasized serious toxicity at the tested exposures.
Targeted oral delivery systems have shown cellular biocompatibility in experimental models.
Reproductive, developmental, and chronic human safety data is absent.

Community Reports / Unknown Risks

Mild injection-site irritation with subcutaneous administration.
Temporary skin redness with topical use.
Occasional gastrointestinal upset at higher oral doses.
Long-term immune, reproductive, organ, and cancer safety is unknown.

KPV Contraindications and Precautions

Do Not Use If You Have

Known hypersensitivity to KPV, alpha-MSH-related peptides, or any formulation component.
Pregnancy or breastfeeding because reproductive and developmental safety data is unavailable.

Use Caution With

Active malignancy, because the colitis-associated cancer findings are context-specific and do not establish general cancer safety.
Immunosuppressive medication, because interaction data is unavailable.
Autoimmune disease or concurrent immune-modulating treatment.
Serious or unexplained gastrointestinal symptoms that require diagnosis rather than self-treatment.

Monitoring

CRP or ESR may be useful when a clinician is already monitoring an inflammatory condition.
Track bowel frequency, pain, bloating, bleeding, food tolerance, and other gut symptoms.
Maintain regular medical follow-up for chronic inflammatory, autoimmune, or gastrointestinal disease.

Drug Interactions

No well-established drug interactions exist because human research is absent. Theoretical interactions are possible with immunosuppressants, biologic therapies, corticosteroids, NSAIDs, and other immune-modulating compounds.

Regulatory Status

KPV is not FDA approved for any indication and has no established human therapeutic dose or approved route of administration.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We consider KPV one of the top gut and anti-inflammatory peptides currently available. It often works faster and cleaner than BPC-157 for stubborn GI issues, leaky gut, and systemic inflammation. Many users report quicker resolution of symptoms and better overall comfort.

For gut health specifically, we find oral KPV paired with BPC-157 to be highly effective. We recommend running this combo 1 or 2 times a year for a 60-day cycle. Injectable KPV is also a great option as it has a pretty clean safety profile and can be cycled regularly for systemic inflammation. It works exceptionally well stacked with GHK-Cu for broader anti-inflammatory and healing synergy.

Well-tolerated and highly effective for the right person. Strong choice when gut health or chronic inflammation is the priority. One of our higher-rated options in this area based on consistent user experiences. We have not seen major downsides reported, which makes it a go-to for gut-focused protocols.